drugset / Trial / NCT05232032
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
Phase 2
Recruiting
112 enrolled
Mclean Hospital
Brown University · collabMassachusetts General Hospital · collabMassachusetts Institute of Technology · collabNational Institute of Mental Health (NIMH) · collabUniversity of Washington · collab
RandomizedParallel-groupTriple-blindBasic science
Summary
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
Timeline
- Start
- 2025-02-01
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nociceptin Receptor Antagonist | Unknown | 40 mg | — |